Budesonide Inhaler Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Budesonide Inhaler Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. According to World Health Organization (WHO), asthma is not just a public health problem for high income countries, as it occurs in all countries regardless of level of development. Over 80% of asthma deaths occur in low and lower-middle income countries. Asthma is under-diagnosed and under-treated, creating a substantial burden to individuals and families and possibly restricting individuals’ activities for a lifetime.
Market Dynamics
The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1000 deaths every day and affects as many as 339 million people worldwide.
Furthermore, major players in the market are focused on developing new drug combinations for paediatric use. For instance, in January 2021, AstraZeneca announced that the U.S. FDA approved Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of asthma in paediatric patients aged 6 to 12 years. Budesonide/formoterol is already approved in the U.S. to treat asthma in patients 12 years and older and for the maintenance treatment of airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD) in adults.
However, product recalls due to failure to meet regulatory guidelines is expected to hinder the market growth. For instance, in 2014, AstraZeneca’s PULMICORT RESPULES (budesonide inhalation suspension) was recalled by the U.S. FDA as budesonide may be above or below the specification range, which can be harmful for the patients.
Key features of the study:
This report provides in-depth analysis of the budesonide inhaler market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global budesonide inhaler market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global budesonide inhaler market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for budesonide inhaler market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Budesonide Inhaler Market, By Product Type:
Inhalants
Nebulizer
Global Budesonide Inhaler Market, By Dosage:
Aerosols
Dry Powder
Suspension
Spray
Global Budesonide Inhaler Market, By Strength:
0.25 mg
0.5 mg
1.0 mg
Global Budesonide Inhaler Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Budesonide Inhaler Market, By Region:
North America
By Country:
U.S.
Canada
By Product Type:
Inhalants
Nebulizer
By Dosage:
Aerosol
Dry Powder
Suspension
Spray
By Strength:
0.25 mg
0.5 mg
1.0 mg
By Distributional Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Inhalants
Nebulizer
By Dosage:
Aerosol
Dry Powder
Suspension
Spray
By Strength:
0.25 mg
0.5 mg
1.0 mg
By Distributional Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Inhalants
Nebulizer
By Dosage:
Aerosol
Dry Powder
Suspension
Spray
By Strength:
0.25 mg
0.5 mg
1.0 mg
By Distributional Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Inhalants
Nebulizer
By Dosage:
Aerosol
Dry Powder
Suspension
Spray
By Strength:
0.25 mg
0.5 mg
1.0 mg
By Distributional Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Inhalants
Nebulizer
By Dosage:
Aerosol
Dry Powder
Suspension
Spray
By Strength:
0.25 mg
0.5 mg
1.0 mg
By Distributional Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Africa
By Country:
South Africa
Central Africa
North Africa
By Product Type:
Inhalants
Nebulizer
By Dosage:
Aerosol
Dry Powder
Suspension
Spray
By Strength:
0.25 mg
0.5 mg
1.0 mg
By Distributional Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Company Profiles
Pfizer Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Cipla Limited
Lupin Limited
Cosmo Pharmaceuticals
Takeda Pharmaceutical Company Ltd.
Manus Aktteva Biopharma LLP
Abbott Laboratories
Lunan Better Pharmaceutical
Novartis International AG (Sandoz)
Mylan N.V.
Skyepharma,
AstraZeneca Plc.
Chiesi Farmaceutici S.p.A.
Orion Corporation
Santarus Inc.
Synmosa Biopharma Corporation
Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.